PMID- 31130713
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 8
IP  - 5
DP  - 2019 May 26
TI  - Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in 
      Rheumatoid Arthritis Patients.
LID - 10.3390/jcm8050751 [doi]
LID - 751
AB  - OBJECTIVE: Rheumatoid arthritis and periodontal disease are associated together, 
      but the effect of therapy provided for one disease to the second one remained 
      under-investigated. This study investigated effect of infliximab therapy used to 
      treat rheumatoid arthritis (RA) on various biomarkers of periodontal disease (PD) 
      severity including serologies of Porphyromonas gingivalis and Prevotella 
      intermedia and matrix metalloproteinase 3. METHODS: Seventy nine RA patients were 
      enrolled at the time to start infliximab therapy and the 28 joint disease 
      activity score (DAS28), anti-cyclic citrullinated petides 2nd generation 
      (anti-CCP2), anti-P. gingivalis antibody, and Matrix metalloproteinase 3 (MMP-3) 
      were monitored before and at 6 months of infliximab therapy. Joint damage and 
      severe periodontal disease were assessed at baseline. Anti-CCP2, anti-P. 
      gingivalis antibody, and MMP-3 were determined by enzyme-linked immunosorbent 
      assay (ELISA). RESULTS: At baseline, anti-CCP2 titers were associated with 
      anti-P. gingivalis lipopolysaccharide (LPS)-specific antibodies titers (p < 
      0.05). Anti-P. gingivalis antibodies were not significantly correlated with 
      clinical, biological, or destruction parameters of RA disease. At 6 months of 
      infliximab therapy, MMP-3 level decreased (from 119 +/- 103 ng/mL to 62.44 +/- 52 
      ng/mL; p < 0.0001), whereas P. gingivalis antibody levels remained at the same 
      level. DAS28 and inflammation markers C-reactive protein (CRP) and Erythrocyte 
      sedimentation rate (ESR) also decreased significantly during infliximab therapy 
      (p < 0.05) as anti-CCP2 levels (p < 0.001). Only high MMP-3 level at baseline was 
      associated with infliximab efficacy (p < 0.01). CONCLUSION: MMP-3 level can be a 
      useful marker of the efficacy of infliximab in RA patients. The treatment did not 
      affect anti-P. gingivalis antibodies.
FAU - Rinaudo-Gaujous, Melanie
AU  - Rinaudo-Gaujous M
AD  - GIMAP EA3064, Laboratory of Immunology and Immunomonitoring, CIC CIE3 Inserm 
      Vaccinology, Hopital Nord, CHU Saint-Etienne, 42270 Saint-Priest-en-Jarez, 
      France. melanie.rinaudogaujous@chpg.mc.
FAU - Blasco-Baque, Vincent
AU  - Blasco-Baque V
AD  - Institute of Cardiovascular and Metabolic Diseases, CHU Rangueil, 31400 Toulouse, 
      France. vincent.blasco@inserm.fr.
FAU - Miossec, Pierre
AU  - Miossec P
AD  - Clinical Immunology Unit, Departments of Immunology and Rheumatology, Hopital 
      Edouard Herriot, CHU Lyon, 69003 Lyon, France. pierre.miossec@univ-lyon1.fr.
FAU - Gaudin, Philippe
AU  - Gaudin P
AD  - Department of Rheumatology, CHU Grenoble, 38130 Echirolles, France. 
      pgaudin@chu-grenoble.fr.
FAU - Farge, Pierre
AU  - Farge P
AD  - Faculty of Odontology, University Lyon I., 69622 Villeurbanne, France. 
      pierre.farge@univ-lyon1.fr.
FAU - Roblin, Xavier
AU  - Roblin X
AD  - Department of Gastroenterology, Hopital Nord, CHU Saint-Etienne, 42270 
      Saint-Priest-en-Jarez, France. xavier.roblin@chu-st-etienne.fr.
FAU - Thomas, Thierry
AU  - Thomas T
AD  - Department of Rheumatology, Hopital Nord, CHU Saint-Etienne, 42055 Saint-Etienne, 
      France. thierry.thomas@chu-st-etienne.fr.
AD  - INSERM U1059, Universite de Lyon-Universite Jean Monnet, 42023 Saint-Etienne, 
      France. thierry.thomas@chu-st-etienne.fr.
FAU - Paul, Stephane
AU  - Paul S
AD  - GIMAP EA3064, Laboratory of Immunology and Immunomonitoring, CIC CIE3 Inserm 
      Vaccinology, Hopital Nord, CHU Saint-Etienne, 42270 Saint-Priest-en-Jarez, 
      France. stephane.paul@chu-st-etienne.fr.
FAU - Marotte, Hubert
AU  - Marotte H
AUID- ORCID: 0000-0003-1177-9497
AD  - Department of Rheumatology, Hopital Nord, CHU Saint-Etienne, 42055 Saint-Etienne, 
      France. hubert.marotte@chu-st-etienne.fr.
AD  - INSERM U1059, Universite de Lyon-Universite Jean Monnet, 42023 Saint-Etienne, 
      France. hubert.marotte@chu-st-etienne.fr.
LA  - eng
PT  - Journal Article
DEP - 20190526
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC6571563
OTO - NOTNLM
OT  - Porphyromonas gingivalis
OT  - Rheumatoid arthritis
OT  - infliximab
OT  - matrix metalloproteinase 3
OT  - periodontal disease
COIS- The authors declare no conflict of interest.
EDAT- 2019/05/28 06:00
MHDA- 2019/05/28 06:01
PMCR- 2019/05/26
CRDT- 2019/05/28 06:00
PHST- 2019/04/05 00:00 [received]
PHST- 2019/05/21 00:00 [revised]
PHST- 2019/05/23 00:00 [accepted]
PHST- 2019/05/28 06:00 [entrez]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2019/05/28 06:01 [medline]
PHST- 2019/05/26 00:00 [pmc-release]
AID - jcm8050751 [pii]
AID - jcm-08-00751 [pii]
AID - 10.3390/jcm8050751 [doi]
PST - epublish
SO  - J Clin Med. 2019 May 26;8(5):751. doi: 10.3390/jcm8050751.